If you have been reading about metabolic modulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
== Side effects == During treatment, gastrointestinal disorders can be observed: dyspepsia, nausea, vomiting, diarrhea . These disorders generally regress with the simple decrease in the dose taken, or with the temporary suspension of the treatment. Other adverse events related to hypersensitivity reactions have also been reported : among these skin rashes, skin rash, fever, arthralgia (joint pain). Rare cases of agranulocytosis have also been reported in medical literature. The rarity of the latter adverse effect led several authors to conclude that perhaps there could have been methodological errors in risk assessments.
=== Pharmacodynamics === Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors. It is selective for the β1-adrenergic receptor and has intrinsic sympathomimetic activity. Carteolol has also been found to act as a serotonin 5-HT1A and 5-HT1B receptor antagonist in addition to being a beta blocker.
== Early life == Born in Boston, Massachusetts, as the only son of Janice (née Hare) and Robert Bagwell, Jeff Bagwell and his family moved to Killingworth, Connecticut, when he was one year old. Much of Bagwell's family is from the Greater Boston area, including both his parents, and are avid fans of the Boston Red Sox. His favorite baseball player, Carl Yastrzemski, was a longtime left fielder for the Red Sox. Robert, from Watertown, pitched college baseball at Northeastern University and as a semi-professional. Janice, a police officer, grew up in Newton and played softball in local Boston leagues until her 20s. Bagwell's parents divorced when he was 11. Precocious and demonstrating much athletic ability early in life, he played a wide variety of sports as a youth. Recalled Janice, Jeff "could throw a ball before he could walk. When he was six months old, we'd throw a ball to him and he would throw it back." Bagwell graduated from Xavier High School, a private all-male Catholic school located in Middletown, Connecticut. A versatile athlete, he excelled at soccer, setting the school goal-scoring mark, played shortstop, and lettered in basketball. In early 1989, Bagwell was honored by Xavier for his character and generosity. He also excelled in American Legion Baseball under coach Fred Tremalgia for Post 75 in Middletown and went on to be named the 2003 American Legion Baseball Graduate of the Year.
== Contraindications == Plecanatide has not been shown to be safe or effective in persons 6 years to 18 years of age. Use of plecanatide by persons under the age of 6 poses a serious dehydration risk and studies have demonstrated plecanatide can cause death in juvenile mice due to this dehydrating effect. Use of plecanatide is also contraindicated in persons who are suspected of having a mechanical gastrointestinal obstruction.
A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a GnRH modulator that blocks the GnRH receptor resulting in an immediate drop in gonadotropin (FSH, LH) secretion. GnRH antagonists are primarily used in IVF treatments to block natural ovulation.
Sources: en.wikipedia.org
=== Cultivator model === Beyond "ORF-first" and "transcription-first" scenarios, the proposed "cultivator model" emphasises that selection acting on regulatory environments of nearby pre-existing genes can promote stepwise fixation of new transcripts and, more rarely, protein-coding de novo genes.
===== The breast mound ===== The breast-tissue matrix consists of engineered tissues of complex, implanted, biocompatible scaffolds seeded with the appropriate cells. The in-situ creation of a tissue matrix in the breast mound is begun with the external vacuum expansion of the mastectomy defect tissues (recipient site), for subsequent seeding (injecting) with autologous fat grafts of adipocyte tissue. A 2010 study, reported that serial fat-grafting to a pre-expanded recipient site achieved (with a few 2-mm incisions and minimally invasive blunt-cannula injection procedures), a non-implant outcome equivalent to a surgical breast reconstruction by autologous-flap procedure. Technically, the external vacuum expansion of the recipient-site tissues created a skin envelope as it stretched the mastectomy scar, and so generated a fertile breast-tissue matrix to which were injected large-volume fat grafts (150–600 ml) to create a breast of natural form, look, and feel. The fat graft breast reconstructions for 33 women (47 breasts, 14 irradiated), whose clinical statuses ranged from zero days to 30 years post-mastectomy, began with the pre-expansion of the breast mound (recipient site) with an external vacuum tissue-expander for 10 hours daily, for 10–30 days before the first grafting of autologous fat. The breast mound expansion was adequate when the mastectomy scar tissues stretched to create a 200–300 ml recipient matrix (skin envelope), that received a fat-suspension volume of 150–600 ml in each grafting session.
Childhood problems related to sickle cells disease were not reported until the 1930s, even though this could not have been uncommon in African-American populations. Memphis physician Lemuel Diggs, a prolific researcher into sickle cell disease, first introduced the distinction between sickle cell disease and trait in 1933. Until 1949, the genetic characteristics had not been elucidated by James V. Neel and E.A. Beet. 1949 was the year when Linus Pauling described the unusual chemical behaviour of haemoglobin S, and attributed this to an abnormality in the molecule itself. The molecular change in HbS was described in 1956 by Vernon Ingram. The late 1940s and early 1950s saw further understanding in the link between malaria and sickle cell disease. In 1954, the introduction of haemoglobin electrophoresis allowed the discovery of particular subtypes, such as HbSC disease. Large-scale natural history studies and further intervention studies were introduced in the 1970s and 1980s, leading to widespread use of prophylaxis against pneumococcal infections among other interventions. Bill Cosby's Emmy-winning 1972 TV movie, To All My Friends on Shore, depicted the story of the parents of a child with sickle cell disease. The 1990s had the development of hydroxycarbamide, and reports of cure through bone marrow transplantation appeared in 2007. Some texts refer to it as drepanocytosis.
After experiencing patella tendinitis in his knee during 2016, Hibberd was eased back into pre-season training. In addition to sustaining a hamstring injury which limited his training further and he was forced to miss the opening match of the 2017 JLT Community Series. He played his first match in Melbourne colours in Melbourne's second match of the JLT Community Series, which was a fifty-four point win against Carlton at Casey Fields. A few days later, he suffered an achilles injury at training, which forced him to miss five weeks of football. He returned to playing via the VFL with Melbourne's affiliate team, the Casey, in the round one clash against Williamstown at Burbank Oval, in which he recorded twenty-five disposals and was one of Casey's best players according to elite performance manager, Dave Misson. He spent just the one week in the VFL before making his debut for Melbourne in the Anzac Day eve match against Richmond at the Melbourne Cricket Ground in round five where he recorded twenty-seven disposals, eight rebound 50s, six marks and a goal. He was named Melbourne's best player by Herald Sun journalist, Sam Landsberger, and was named in AFL Media's team of the week. He played every match for the remainder of the season to finish with eighteen games and averaged career-highs in disposals (27.4) and rebound 50s (6.8), the latter of which ranked second in the league; furthermore he averaged the highest metres gained per match (545.7) in the league.
Observe the value of the friction factor for laminar flow at a Reynolds number of 1000. If the value of the friction factor is 0.064, then the Darcy friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.064 are the numerator in the formula for the laminar Darcy friction factor: fD = 64/Re. If the value of the friction factor is 0.016, then the Fanning friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.016 are the numerator in the formula for the laminar Fanning friction factor: f = 16/Re. The procedure above is similar for any available Reynolds number that is an integer power of ten. It is not necessary to remember the value 1000 for this procedure—only that an integer power of ten is of interest for this purpose.
Sources: en.wikipedia.org
While a variety of theories have been postulated for the etymological origins of Canada, the name is now accepted as coming from the St. Lawrence Iroquoian word kanata, meaning 'village' or 'settlement'. In 1535, Indigenous inhabitants of the present-day Quebec City region used the word to direct French explorer Jacques Cartier to the village of Stadacona. Cartier later used the word Canada to refer not only to that particular village but to the entire area subject to Donnacona (the chief at Stadacona); by 1545, European books and maps had begun referring to this small region along the Saint Lawrence River as Canada. From the 16th to the early 18th century, Canada referred to the part of New France that lay along the Saint Lawrence River. Following the British conquest of New France, this area was known as the British Province of Quebec from 1763 to 1791. In 1791, the area became two British colonies called Upper Canada and Lower Canada. These two colonies were collectively referred to as the Canadas until their union as the Province of Canada in 1841. Upon Confederation in 1867, Canada was adopted as the legal name for the new country at the London Conference and the word dominion was conferred as the country's title, reflecting its status as a self-governing nation within the British Empire.
vasoconstriction temporary blockage of a hole in a damaged blood vessel by a platelet plug blood coagulation (formation of fibrin clots) Coagulation, the changing of blood from a liquid to a gel which forms the fibrin clots, is essential to hemostasis. Intact blood vessels moderate blood's tendency to form clots. The endothelial cells of intact vessels prevent blood clotting with a heparin-like molecule and thrombomodulin, and prevent platelet aggregation with nitric oxide and prostacyclin. When endothelium of a blood vessel is damaged, the endothelial cells stop secretion of coagulation and aggregation inhibitors and instead secrete von Willebrand factor, which initiates the maintenance of hemostasis after injury. These processes seal the injury or hole until tissues are healed.
=== Video games === In April 2026, Austin was revealed to be added to Fortnite. He is the sixth WWE outfit added to the game following -- John Cena, Becky Lynch, Bianca Belair, Cody Rhodes and The Undertaker. Dwayne Johnson appears in the game but not as himself or The Rock but in an acting role using his likeness for the character The Foundation.
=== Unit operations and unit processes === Food processing results in physical and (bio)chemical changes in food materials independently whether processing involves home cooking, food services or industrial food manufacturing. Food processing is typically covered by food engineering, biochemical engineering and chemical engineering disciplines. Description of processes relies on understanding physical phenomena occurring in unit operations and kinetics of (bio)chemical reactions in unit processes which form the building blocks of food processing. Unit operations in food processing are building blocks of operations resulting in physical changes in food materials. Unit operations are governed by general physical laws and include heat transfer and mass transfer required in different operations, such as separation processes, mixing and crystallization. Unit processes in food processing consist of unit operations and biochemical processes and chemical reactions resulting in (bio)chemical changes in food materials. In chemical reaction engineering multiple unit operations are combined with unit processes to achieve the desired chemical changes. Unit operations and unit processes are the premise of food processing systems. Multiple unit operations are often needed to carry out food processing designed to result in physical changes. Biochemical and chemical changes during food processing, such as loss of vitamin C, can accompany intended physical modifications, e.g., during heat treatments.
===== MeSH D08.811.399.894 – racemases and epimerases (EC 5.1) ===== MeSH D08.811.399.894.200 – amino acid isomerases MeSH D08.811.399.894.200.200 – alanine racemase MeSH D08.811.399.894.500 – carbohydrate epimerases MeSH D08.811.399.894.500.700 – UDP-glucose 4-epimerase
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.